Preliminary clinical experience with a new natural compound in the treatment of oesophagitis and gastritis: Symptomatic effect

Trends in Medicine

Volumn 9, Issue 4, 2009, Pages 219-225

  Palmieri, Beniamino ^a   Corbascio, Domenico ^b   Capone, Stefania ^a   Lodi, Daniele ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Pavullo Hospital   (Italy)

Author keywords

Chondroitin sulphate; Gastroesophageal reflux disease (GERD); Hyaluric acid

Indexed keywords

ANTACID AGENT; CHONDROITIN SULFATE; HYALURONIC ACID; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; STEROID;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS MUCOSA; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH MUCOSA; TREATMENT OUTCOME; ULCER HEALING;

EID: 75749145089     PISSN: 15942848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Tomomitsu T, Tomiyasu A, Tomoyuki S, et al. Association of endoscopic appearances with dyspeptic symptoms. J Gastroenterol 2008; 43:208-215.
2. Babkin BP, Komarov SA. The influence of gastric mucous on peptic digestion. Can Med Ass J 1932; 27:463-466.
3. Crandall LA, Roberts GM. Observations on administration of chondroitin in peptic ulcers. Proc Soc Exp Biol Med 1933; 30:704-708.
4. Levey S, Sheinfeld S. The inhibition of proteolytic action of pepsine by sulphate-containing Polysaccharides. Gastroenterology 1954; 27 625-628.
5. Bonfils S, Lambling A. Activitè therapeutique d'un inhibiteur de la proteolyse peptique (polysaccharide c16). Etude sur le douleur et l'image radiologique de l'ulcere gastroduodenale. Therapie 1960; 15 612-616.
6. Benati E, Bianchi G. Effetti terapeutici del condroitinsolfato di Sodio nell'ulcera gastroduodenale. Gazz.Med Ital 1963; 122 149-153.
7. Baldini E, Tincani GP. Trattamento dell'ulcera gastroduodenale con il condroitinsolfato di sodio. Min Gastroent. 1963; 9:25-29.
8. Pirola P, Pozzi G. Sul trattamento di affezioni ga stroduodenali con condroitinsolfato sodico. Gazz Med Ital 1963; 18:141-149.
9. Fialkova MA, Smirnova TIU, Ivanova GI, et al. The effect of chondroitin sulfate preparations on wound healing and the strength of the surgical scar. Biull Eksp Biol Med 1989; 108(9):350.
10. Harrison SE, Soll DB, Shayegan M, et al. A new and effective protective agent for intraocular lens insertion. Ophthalmology 1982; 89:1254-1260.
11. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage 2002; 10:768-777.
12. Barthe L, Woodley J, Lavit M, et al. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung 2004; 54:286-292.
13. Sekino T, Murata K. Age-dependent constitutional change in acidic glycosaminoglycans in human esophagus. Digestion 1978; 18(5-6):319-328.
14. Sekino T, Murata K, Saito Y. Acidic glycosaminoglycans in human esophagus tissue. Tohoku J Exp Med 1979; 127:273-280.
15. Steinhoff G, Ittah B, Rowan S. The efficacy of intravesicular sterile sodium chondroitin sulfate 0.2% in potassium tested positive patients with interstitial cystitis. Adv Exp Med Biol 2003; 539 (Pt B):731-739.